Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adult Solid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × carotuximab × Clear all
NCT03181308 2020-06-24

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Tracon Pharmaceuticals Inc.

Phase 1 Completed
11 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03780010 2019-10-28

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Tracon Pharmaceuticals Inc.

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01332721 2018-12-05

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Tracon Pharmaceuticals Inc.

Phase 1 Completed
38 enrolled 8 charts
Other solid neoplasm

Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡